Title: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation.
The aim of the SHERLOCK trial is to assess the activity and tolerability of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar in non-squamous metastatic NSCLC with KRAS G12C mutation.
KRAS G12C positive newly diagnosed, treatment naïve metastatic (Stage IV) non-squamous NSCLC or recurrent non-squamous NSCLC with no disease progression for at least 6 months following prior curative lung surgery and (neo)adjuvant chemotherapy, or prior curative concurrent chemoradiotherapy and immunotherapy maintenance, for non-resectable stage III cancer.
Substudy status: Recruiting
Registration number: ACTRN12622000973718